In glioblastoma, neutrophils (CD66b+ and CD16+), a subset of myeloid-derived suppressor cells, upregulate the S100A4 protein, which suppresses the mesenchymal phenotype and facilitates acquired resistance to anti-VEGF therapy (57). The gene discussed is VEGFA; the disease is glioblastoma.